Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CALIBRATE-HF
NL-OMON61476Phase 2Not yet recruiting
- Sponsor
- Cardurion Pharmaceuticals
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of CRD-4730 in heart failure with reduced ejection fraction (HFrEF), sponsored by Cardurion Pharmaceuticals. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
CRD-4730
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NL-OMON61476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61476.